Ert Pompe denied for missing prior authorization by Humana?

Humana's specific coverage criteria for ert pompe are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Requires Prior Authorization for Pompe Disease ERT — and How to Navigate It

A prior-authorization-required denial means Humana did not receive an approved PA before the therapy was administered or dispensed, or the PA request was submitted but not yet adjudicated. For enzyme replacement therapy for Pompe disease, prior authorization is routine — Humana, like most payers covering high-cost rare-disease infusion therapies, requires documented medical-necessity review before approving coverage.

If the denial is for a retro-authorization (treatment already given without PA), the appeal process is different from a prospective PA request. Both are addressable, but the documentation and framing differ.

## Federal Appeal Rights

ACA Section 2719 and ERISA Section 503 apply to PA-related adverse benefit determinations. If a PA request was denied on clinical grounds, internal and external appeal rights attach. External review must generally be initiated within four months of the final internal adverse determination. Expedited prior authorization and appeal (typically 72 hours) is available when the standard timeline would seriously jeopardize health — highly relevant for a patient who has missed or is about to miss an infusion.

## What to Gather

For a prospective PA request or appeal of a PA denial: - Diagnosis confirmation — genetic testing, enzyme-activity assay, or biopsy results establishing Pompe disease. - Clinical severity documentation — pulmonary function trends, motor assessments, and other functional measures from the chart showing current disease burden. - Prior-treatment history — any prior ERT experience, including product, dates, and clinical response. - Prescriber medical-necessity letter — addressed to Humana's clinical reviewer, with explicit responses to each criterion in Humana's PA coverage policy. - Humana's current PA criteria — obtain from Humana's provider portal or policy library; build your submission against every listed criterion.

For a retro-authorization appeal: - All of the above, plus documentation of why PA was not obtained in advance (emergency, urgent clinical need, prescriber or payer error) and the clinical record from the date of treatment.

## Criteria-Mapping Structure

For every criterion in Humana's PA policy, provide a direct answer from the clinical record or prescriber letter. Do not submit a PA or appeal letter that describes Pompe disease generally — Humana's reviewer needs patient-specific facts mapped to each policy requirement. If the policy requires a specific diagnostic test, ensure the chart documents that test; if results are pending, state the plan and timeline.

## Process and Timeline

1. For a prospective PA: submit the complete package to Humana's prior-authorization unit; request expedited review if clinically warranted. 2. For a denied PA: file the internal appeal within the plan's deadline, with the criteria-mapping documentation. 3. For a retro-authorization: file within the shorter retro-appeal window Humana specifies (often 60 days) and address the clinical urgency that precluded advance authorization. 4. If denied internally, request external review within four months.